SNK develops brand identity and appearance for ETH spin-off Cytosurge
SNK developed the brand identity for Cytosurge and positions the brand in its market.
Scientists from the Institute of Biomedical Engineering at ETH Zurich have developed a nanosyringe whose hollow needle is only a few atoms wide at the tip. This enables drug substances, DNA and RNA to be injected into or extracted from individual cells. In addition to biological applications, the process could also be used in microelectronics. This groundbreaking technology is now being further developed by the start-up company Cytosurge and brought to market maturity.
SNK works with the client to develop Cytosurge's brand identity and position the brand in its market. Based on this, the agency designed the logo and the entire brand identity. During implementation, SNK developed the brand's core messages and designed important communication channels, such as the website. From the outset, the brand demonstrates Cytosurge's enormous potential and high level of professionalism and thus provides significant support for the development of the company.
SNK works with the client to develop Cytosurge's brand identity and position the brand in its market. Based on this, the agency designed the logo and the entire brand identity. During implementation, SNK developed the brand's core messages and designed important communication channels, such as the website. From the outset, the brand demonstrates Cytosurge's enormous potential and high level of professionalism and thus provides significant support for the development of the company.
